Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18 F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction.

Autor: Sullivan R; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada.; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada., Hou J; Lakehead University and Thunder Bay Regional Health Research Institute, Thunder Bay, Ontario, Canada., Yu L; London Regional Cancer Program, London, Ontario, Canada., Wilk B; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada.; Department of Medical Biophysics, Western University, London, Ontario, Canada., Sykes J; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada., Biernaski H; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada., Butler J; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada., Kovacs M; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada.; Department of Medical Biophysics, Western University, London, Ontario, Canada., Hicks J; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada.; Department of Medical Biophysics, Western University, London, Ontario, Canada., Thiessen JD; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada.; Department of Medical Biophysics, Western University, London, Ontario, Canada., Dharmakumar R; Indiana School of Medicine, Indianapolis, Indiana; and., Prato FS; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada.; Department of Medical Biophysics, Western University, London, Ontario, Canada., Wisenberg G; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada., Luyt LG; London Regional Cancer Program, London, Ontario, Canada.; Departments of Chemistry, Oncology, and Medical Imaging, Western University, London, Ontario, Canada., Dhanvantari S; Imaging Research Program, Lawson Health Research Institute, London, Ontario, Canada; sdhanvan@lawsonimaging.ca.; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.; Department of Medical Biophysics, Western University, London, Ontario, Canada.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Oct 01; Vol. 65 (10), pp. 1633-1639. Date of Electronic Publication: 2024 Oct 01.
DOI: 10.2967/jnumed.124.267578
Abstrakt: The peptide hormone ghrelin is produced in cardiomyocytes and acts through the myocardial growth hormone secretagogue receptor (GHSR) to promote cardiomyocyte survival. Administration of ghrelin may have therapeutic effects on post-myocardial infarction (MI) outcomes. Therefore, there is a need to develop molecular imaging probes that can track the dynamics of GHSR in health and disease to better predict the effectiveness of ghrelin-based therapeutics. We designed a high-affinity GHSR ligand labeled with 18 F for imaging by PET and characterized its in vivo properties in a canine model of MI. Methods: We rationally designed and radiolabeled with 18 F a quinazolinone derivative ([ 18 F]LCE470) with subnanomolar binding affinity to GHSR. We determined the sensitivity and in vivo and ex vivo specificity of [ 18 F]LCE470 in a canine model of surgically induced MI using PET/MRI, which allowed for anatomic localization of tracer uptake and simultaneous determination of global cardiac function. Uptake of [ 18 F]LCE470 was determined by time-activity curve and SUV analysis in 3 regions of the left ventricle-area of infarct, territory served by the left circumflex coronary artery, and remote myocardium-over a period of 1.5 y. Changes in cardiac perfusion were tracked by [ 13 N]NH 3 PET. Results: The receptor binding affinity of LCE470 was measured at 0.33 nM, the highest known receptor binding affinity for a radiolabeled GHSR ligand. In vivo blocking studies in healthy hounds and ex vivo blocking studies in myocardial tissue showed the specificity of [ 18 F]LCE470, and sensitivity was demonstrated by a positive correlation between tracer uptake and GHSR abundance. Post-MI changes in [ 18 F]LCE470 uptake occurred independently of perfusion tracer distributions and changes in global cardiac function. We found that the regional distribution of [ 18 F]LCE470 within the left ventricle diverged significantly within 1 d after MI and remained that way throughout the 1.5-y duration of the study. Conclusion: [ 18 F]LCE470 is a high-affinity PET tracer that can detect changes in the regional distribution of myocardial GHSR after MI. In vivo PET molecular imaging of the global dynamics of GHSR may lead to improved GHSR-based therapeutics in the treatment of post-MI remodeling.
(© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze: MEDLINE
Externí odkaz: